Previous close | 64.58 |
Open | 64.72 |
Bid | 65.93 x 600 |
Ask | 65.96 x 700 |
Day's range | 64.67 - 66.20 |
52-week range | 64.33 - 87.87 |
Volume | |
Avg. volume | 7,181,201 |
Market cap | 82.176B |
Beta (5Y monthly) | 0.23 |
PE ratio (TTM) | 183.22 |
EPS (TTM) | 0.36 |
Earnings date | 08 Aug 2024 |
Forward dividend & yield | 3.08 (4.67%) |
Ex-dividend date | 14 Jun 2024 |
1y target est | 81.29 |
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
REDWOOD CITY, Calif. & SANTA MONICA, Calif., May 09, 2024--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
Unraveling the Financial Dynamics and Strategic Directions of Gilead Sciences Inc (GILD)